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Summary
Background Intensive care units (ICUs) are high-risk areas for transmission of antimicrobial-resistant bacteria, but no 
controlled study has tested the eﬀ ect of rapid screening and isolation of carriers on transmission in settings with best-
standard precautions. We assessed interventions to reduce colonisation and transmission of antimicrobial-resistant 
bacteria in European ICUs.
Methods We did this study in three phases at 13 ICUs. After a 6 month baseline period (phase 1), we did an interrupted 
time series study of universal chlorhexidine body-washing combined with hand hygiene improvement for 6 months 
(phase 2), followed by a 12–15 month cluster randomised trial (phase 3). ICUs were randomly assigned by computer 
generated randomisation schedule to either conventional screening (chromogenic screening for meticillin-resistant 
Staphylococcus aureus [MRSA] and vancomycin-resistant enterococci [VRE]) or rapid screening (PCR testing for MRSA 
and VRE and chromogenic screening for highly resistant Enterobacteriaceae [HRE]); with contact precautions for 
identiﬁ ed carriers. The primary outcome was acquisition of resistant bacteria per 100 patient-days at risk, for which 
we calculated step changes and changes in trends after the introduction of each intervention. We assessed acquisition 
by microbiological surveillance and analysed it with a multilevel Poisson segmented regression model. We compared 
screening groups with a likelihood ratio test that combined step changes and changes to trend. This study is registered 
with ClinicalTrials.gov, number NCT00976638.
Findings Seven ICUs were assigned to rapid screening and six to conventional screening. Mean hand hygiene 
compliance improved from 52% in phase 1 to 69% in phase 2, and 77% in phase 3. Median proportions of patients 
receiving chlorhexidine body-washing increased from 0% to 100% at the start of phase 2. For trends in acquisition of 
antimicrobial-resistant bacteria, weekly incidence rate ratio (IRR) was 0·976 (0·954–0·999) for phase 2 and 1·015 
(0·998–1·032) for phase 3. For step changes, weekly IRR was 0·955 (0·676–1·348) for phase 2 and 0·634 (0·349–1·153) 
for phase 3. The decrease in trend in phase 2 was largely caused by changes in acquisition of MRSA (weekly IRR 
0·925, 95% CI 0·890–0·962). Acquisition was lower in the conventional screening group than in the rapid screening 
group, but did not diﬀ er signiﬁ cantly (p=0·06).
Interpretation Improved hand hygiene plus unit-wide chlorhexidine body-washing reduced acquisition of 
antimicrobial-resistant bacteria, particularly MRSA. In the context of a sustained high level of compliance to hand 
hygiene and chlorhexidine bathings, screening and isolation of carriers do not reduce acquisition rates of multidrug-
resistant bacteria, whether or not screening is done with rapid testing or conventional testing.
Funding European Commission.
Introduction
Antimicrobial-resistant bacteria have become more 
widespread worldwide. Intensive care units (ICUs) are 
especially aﬀ ected by three major groups of highly 
resistant pathogens—meticillin-resistant Staphylococcus 
aureus (MRSA), vancomycin-resistant enterococci (VRE), 
and highly resistant (ie, resistant to third-generation or 
fourth-generation cephalosporins) Enterobacteriaceae 
(HRE). Controlling the spread of these organisms is a 
major public health challenge and often involves labour-
intensive, protracted eﬀ orts. Several control measures 
have been advocated1 including improved adherence to 
standard precautions,2 chlorhexidine body-washing,3–9 
introduction of contact precautions for known carriers of 
antimicrobial-resistant bacteria and putting carriers in 
single-patient rooms,10,11 and rapid detection of carriers at 
admission to ICU combined with isolation of carriers. 
However, evidence for these interventions is mainly 
based on small, quasi-experimental studies. Universal 
screening of patients at ICU admission for antimicrobial-
resistant bacteria followed by contact precautions—a 
costly and labour-intensive intervention—remains the 
most controversial, with conﬂ icting results precluding 
evidence-based recommendations.12
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No controlled study has tested the eﬀ ect of rapid 
screening and isolation of carriers on colonisation with 
antimicrobial-resistant bacteria in settings that already 
have best standard precautions in place. We assessed the 
eﬀ ect of diﬀ erent infection control strategies on 
acquisition of antimicrobial-resistant bacteria in ICUs.
Methods
Study design and participants
We assessed 13 European ICUs between May, 2008, and 
April, 2011, in three phases. Implementation of costly and 
labour-intensive interventions—eg, screening and 
isolation—is probably futile in the absence of good basic 
hygiene. Therefore, after a 6 month baseline period 
(phase 1), we introduced a hygiene improvement pro-
gramme at all ICUs in an interrupted time-series phase 
(phase 2) before beginning a cluster randomised, controlled 
phase (phase 3). In phase 2, we tested the eﬀ ect of optimised 
hand hygiene plus unit-wide implementation of 
chlorhexidine body-washing on acquisition of anti micro-
bial-resistant bacteria. In phase 3, we tested the additional 
eﬀ ect of screening followed by contact precautions for 
identiﬁ ed carriers, using either PCR for MRSA and VRE 
together with chromogenic screening for HRE (rapid 
screening), or chromogenic-based screening for MRSA 
and VRE only (conventional screening).
Interrupted time series are useful if a randomised 
controlled trial is not feasible.13,14 We planned to use a 
stepped-wedge design for phase 2 but this proved 
impractical because of logistical and ﬁ nancial constraints. 
However, we did enrol ICUs consecutively to account for 
seasonal eﬀ ects.
We aimed to include ICUs with a moderate to high 
proportion of resistant bacteria. Adult ICUs with at least 
eight beds were eligible, provided that—of the ICU-acquired 
bacteraemias recorded in 2006 or 2007—MRSA accounted 
for more than 10% of S aureus bacteraemias, VRE accounted 
for more than 5% of enterococcal bacteraemias, or extended-
spectrum β-lactamase resistance accounted for more than 
10% of Entero bacteriaceae bacteraemias.
Each institution’s review board or national ethics 
committee approved the study protocol. Because the 
study involved very little risk of harm to patients, a 
waiver for informed consent was sought and granted for 
all participating centres.
Randomisation and masking
After phase 2, the 13 ICUs were randomly assigned (1:1) to 
the rapid or conventional screening groups. The sequence 
for allocation was based on a computer-generated 
randomisation list, generated by an independent data 
manager who had no other role in the study. We did not 
match ICUs and no masking was used.
Procedures
Surveillance swabs from perineum, nose, and wounds (if 
present) were obtained within 2 days of admission to the 
ICU, then twice per week for 3 weeks, then once per 
week thereafter, for all patients admitted to ICU for 
3 days or more. All surveillance swabs were analysed 
locally, according to a standardised protocol (appendix). 
Chromogenic media was used for detection of MRSA 
(BBL CHROMagar MRSA II; Becton, Dickinson and 
Company, Franklin Lakes, NJ USA), BBL Entero coccosel 
Agar with vancomycin 8 μg/mL for detection of VRE 
(Becton, Dickinson and Company), and Brilliance ESBL 
2 for detection of HRE (Oxoid, Cambridge, UK).15–17 In 
ICUs assigned to rapid screening, Xpert MRSA and 
Xpert VanA/VanB (Cepheid, Sunnyvale, CA, USA) were 
used additionally.18,19
All microbiology laboratories were required to complete 
proﬁ ciency panels.20–22 All ﬁ rst isolates of MRSA, VRE, and 
HRE from surveillance cultures or blood were shipped to 
a central laboratory for species conﬁ rmation, susceptibility 
testing, and genotyping. To assess chlorhexidine 
resistance, the presence of qacA and qacB genes was 
investi gated by PCR at the central laboratory.2,23
After phase 1, we implemented a hand hygiene 
improvement programme and universal daily body-
washing with 0·16 g/L chlorhexidine gluconate for 
6 months (phase 2) in all ICUs. We derived the hand 
hygiene programme from the WHO’s Five Moments for 
Hand Hygiene concept.2–7,24
These interventions continued in phase 3 alongside 
screening and contact precautions for carriers of 
antimicrobial-resistant bacteria (appendix). During 
phases 1 and 2, barrier precautions were based on pre-
study local isolation protocols and were not part of the 
study interventions. During phase 1 and phase 2, 
surveillance cultures were stored and processed with a 
2 month delay to maintain masking of ICU personnel to 
the colonisation status of patients. In phase 3, screening 
results were immediately disclosed to staﬀ  at ICUs. Time 
from acquisition of swabs to start of processing (time-to-
test) and from start of test until reporting of results 
(time-to-result) were recorded for all surveillance 
cultures; the sum of both was the turn-around time of 
tests. Interventions likely to aﬀ ect outcomes (eg, central-
line-associated bloodstream infection bundles or 
ventilator-associated pneumonia bundles, selective 
digestive decontamination, enhanced anti microbial 
steward ship, or mupirocin use) were not introduced 
during the study.
Patients’ demographics, reason for ICU admission, 
length of stay in ICU and in hospital, disposition at 
discharge, and 28 day mortality, as well as occurrence of 
bactaeremia with S aureus, enterococci, and Entero-
bacteriaceae were recorded for all patients. We collected 
weekly point prevalence data for bed occupancy, staﬃ  ng 
ratios, numbers of patients ventilated, invasive devices, 
and isolation details (appendix). Two research nurses in 
each ICU were centrally trained to do hand hygiene 
observations. 15 observation sessions, of 15–30 min, were 
done every month throughout the study at the ICUs. The 
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sessions were randomly scheduled within three 4 h 
periods (0800–1200 h, 1200–1600 h, and 1600–2000 h).
We checked 10% of all electronic case report forms 
against data collected at each ICU, and checked all 
procedures for consistency once during phase 1 and once 
during phase 2. Data were collected through an online 
data entry system, consisting of an independently 
managed secure data processing centre, including 
plausibility checks for data entry.
Colonisation was deﬁ ned as growth on chromogenic 
plates and acquisition was based on chromogenic agar 
results for all phases and both screening groups. If a 
patient was colonised according to the last screening 
culture, we assumed that colonisation persisted until 
discharge from ICU. If a patient was not colonised at the 
last screening culture, the period at risk ended on that 
day. Colonisation and bacteraemia were classed as ICU-
acquired if detected on or after the third day of admission 
to the ICU, after a negative swab. We did not follow up 
patients after discharge from ICU.
The primary endpoint was the number of patients who 
acquired MRSA, VRE, or HRE carriage per 100 patient-
days at risk in ICU. Secondary outcomes included 
incidence density rate of ICU-acquired colonisation and 
bacteraemia for each of MRSA, VRE, and HRE; 
compliance with hand hygiene practices; length of stay in 
ICU; length of stay in hospital; and 28 day mortality. The 
appendix shows further secondary outcomes.
Patients admitted for fewer than 3 days were not 
deemed at risk for ICU-acquired colonisation and 
Phase 1 (n=2043) Phase 2 (n=2072) Phase 3
Conventional screening 
group (n=2348)
Rapid screening 
group (n=2513)
ICU characteristics
Beds occupied 84·7% (18·5) 87·9% (16·6) 84·2% (17·1) 86·6% (18·3)
Nurse:patient ratio 0·55 (0·22) 0·53 (0·19) 0·55 (0·20) 0·55 (0·25)
Location before admission to ICU
Home or private residence 38·2% (36·1–40·4) 35·6% (33·6–37·7) 38·2% (36·3–40·2) 37·2% (35·3–39·1)
Health-care facility 59·1% (56·9–61·2) 60·3% (58·1–62·4) 58·6% (56·6–60·6) 58·6% (56·6–60·5)
Unknown or other 2·7% (2·1–3·5) 4·2% (3·4–5·1) 3·2% (2·6–4·0) 4·3% (3·6–5·1)
Risk factors for colonisation before admission to ICU
Admitted to a hospital for >24 h in the past year 52·6% (50·4–54·8) 47·6% (45·4–49·7) 56·6% (54·5–58·6) 41·4% (39·4–43·3)
Any type of surgery in the past year 20·3% (18·6–22·1) 22·2% (20·4–24·0) 20·9% (19·3–22·6) 18·9% (17·4–20·5)
Urgent or emergency surgery before admission to ICU 17·4% (15·8–19·1) 15·3% (13·8–17·0) 14·8% (13·4–16·3) 17·4% (16·0–19·0)
Patient history
Solid tumour 14·2% (12·8–15·8) 12·0% (10·7–13·5) 13·5% (12·2–14·9) 15·8% (14·5–17·3)
Haematological cancer 3·9% (3·2–4·9) 4·1% (3·3–5·0) 4·2% (3·4–5·1) 4·1% (3·4–4·9)
Haemopoietic stem cell or bone marrow transplant 0·7% (0·4–1·2) 0·8% (0·5–1·3) 0·8% (0·5–1·3) 0·8% (0·5–1·2)
Solid organ transplant 2·2% (1·6–2·9) 1·6% (1·2–2·3) 1·8% (1·4–2·5) 1·5% (1·1–2·0)
HIV/AIDS 1·9% (1·4–2·5) 1·4% (0·9–2·0) 1·4% (1·0–2·0) 1·6% (1·2–2·2)
MRSA colonisation in the past year 3·1% (2·2–3·6) 3·1% (2·4–4·0) 2·8% (2·2–3·6) 4·5% (3·8–5·4)
VRE colonisation in the past year 0·2% (0·1–0·4) 0·2% (0·1–0·6) 0·2% (0·1–0·5) 2·1% (1·6–2·7)
HRE colonisation in the past year 2·3% (1·7–3·1) 2·7% (2·1–3·4) 3·2% (2·5–3·9) 3·0% (2·4–3·7)
Patient demographics
Median age (IQR, years) 65 (50–76) 64 (50–75) 64 (49–76) 65 (51–77)
Men 61·0% (58·9–63·1) 60·0% (57·9–62·1) 60·9% (58·9–62·9) 59·3% (57·4–61·2)
Non-surgical reason for admission to ICU 76·5% (74·6–78·3) 79·8% (78·0–81·5) 81·4% (79·8–82·9) 73·4% (71·7–75·1)
Median APACHE-II score (IQR)* 16 (11–22) 16 (11–22) 15 (10–22) 15 (11–19)
Median SAPS-II (IQR)† 40 (28–54) 38 (27–50) 37 (26–50) 35 (24–48)
Invasive devices (during ﬁ rst 3 days)
Endotracheal tube 60·4% (58·2–62·5) 60·4% (58·3–62·5) 59·4% (57·4–61·3) 52·1% (50·2–54·1)
Tracheostomy tube 4·2% (3·4–5·2) 4·3% (3·5–5·3) 3·2% (2·6–4·0) 5·8% (5·0–6·8)
Central venous catheter 69·8% (67·7–71·7) 68·3% (66·3–70·3) 61·5% (59·5–63·5) 73·5% (71·7–75·2)
Arterial intravascular catheter 64·2% (62·1–66·3) 63·4% (61·3–65·5) 59·2% (57·2–61·2) 69·0% (67·2–70·8)
Data are mean (95% CI), unless otherwise stated. Data were taken from all patients admitted for at least 3 days. ICU=intensive care unit. APACHE=Acute Physiology and 
Chronic Health Evaluation. SAPS=Simpliﬁ ed Acute Physiology Score. MRSA=meticillin-resistant Staphylococcus aureus. VRE=vancomycin-resistant enterococci. HRE=highly 
resistant Enterobacteriaceae. *Data available for 709 patients in phase 1, 780 in phase 2, and 1724 in phase 3. †Data available for 1334 patients in phase 1, 1292 in phase 2, 
and 3134 in phase 3.
Table 1: Baseline characteristics
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bacteraemia, and were excluded from the analyses of 
ICU-acquired endpoints, though they were subject to 
the interventions. For secondary outcomes, patients 
were deemed at risk for acquisition of individual 
pathogens if not colonised or infected with that 
pathogen at hospital admission.
Statistical analysis
We calculated that 960 patients per ICU would be needed 
to show a 10% absolute diﬀ erence in the probability of 
colonisation between the randomised groups with a two-
sided test and assuming a type I error of 0·05, a type II 
error of 0·2, and an intracluster correlation coeﬃ  cient of 
0·05. We assessed outcomes with a multilevel Poisson 
segmented regression analysis, allowing for random 
variation between ICUs for baseline levels and trends. 
We assessed both step changes in acquisition rate per 
100 patient-days at risk and changes in trends of 
acquisition rate per 100 patient-days at risk (rate of 
change of the log weekly acquisition rate) after the 
introduction of each intervention.14
Potential confounding factors—calendar month and 
patient and ward characteristics—were ﬁ tted as 
covariates. We did a post-hoc exploratory analysis with 
time-dependent Cox regression to assess the eﬀ ects of 
colonisation pressure on acquisition. We did the analyses 
with STATA (version 11), and SPSS (version 17).
This study is registered with ClinicalTrials.gov, number 
NCT00976638.
Role of the funding source
The sponsors had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
We screened 14 390 patients for eligibility, of whom 
8976 were admitted to the ICU for at least 3 days (table 1). 
8519 patients had at least one nasal, rectal, or wound 
swab during ICU admission and were therefore analysed 
(ﬁ gure 1, table 2). ICUs varied from completely open to 
all single-patient rooms.
We obtained at least one nasal swab from 8517 (95%) 
of 8976 patients, a perineal swab from 8501 (95%) of 
8976 patients, and a wound swab from 931 (10%) 
of 8976 patients. Of 41 558 hand hygiene opportunities, 
mean compliance was 52% in phase 1, 69% in phase 2, 
and 77% in phase 3 (ﬁ gure 2, appendix p 11). We found no 
evidence of a change of behaviour of health-care workers 
as a result of observation (ie, the Hawthorne eﬀ ect; data 
not shown). Based on 1188 point-prevalence 
measurements, median adherence to chlorhexidine body-
washing was 0% in phase 1, 100% in phase 2, and 100% in 
phase 3 (appendix).
In ICUs assigned to rapid screening, proportions of 
patients for whom contact precautions were taken 
increased for all antimicrobial-resistant bacteria compared 
with phase 2. In ICUs assigned to conventional screening, 
only MRSA-related and VRE-related contact precautions 
increased, consistent with protocol (appendix). The 
proportion of patients in single rooms varied from 15% to 
22%. This proportion exceeds the proportion of carriers, 
Phase 1
n=3215
n=2043
n=1962
n=1688
Phase 2
n=3345
n=2072
n=1926
n=1681
Phase 3
(conventional
screening)
n=3710
n=2348
n=2280
n=2029
Phase 3
(rapid screening)
n=4120
n=2513
n=2351
n=2007
Assessed for eligibility
≥3 days in ICU
Patients analysed*
At risk for acquiring
colonisation
with AMRB
Figure 1: Study proﬁ le
Patients at risk for acquiring colonisation with AMRB excludes all patients colonised at admission with any of MRSA, 
VRE, HRE, or in whom a ﬁ rst (admission) swab was taken after the ﬁ rst 2 days of ICU stay and was positive. 
AMRB=antimicrobial-resistant bacteria. ICU=intensive care unit. MRSA=meticillin-resistant Staphylococcus aureus. 
VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. *Admitted for at least 3 days, for 
whom admission and discharge data were available and of whom at least one nasal, rectal, or wound swab was 
obtained during ICU admission. 
 Phase 1 Phase 2 Phase 3
At ICUs using conventional screening n=979 n=1020 n=2280
Any (%) 13·5% (11·5–15·8) 12·5% (10·6–14·6) 10·3% (9·1–11·6)
MRSA (%) 5·4% (4·2–7·0) 3·7% (2·7–5·1) 4·1% (3·3–5·0)
VRE (%) 3·3% (2·3–4·6) 2·9% (2·1–4·2) 1·1% (0·7–1·6)
HRE 
Total (%) 6·8% (5·4–8·6) 7·0% (5·6–8·7) 6·0% (5·1–7·1)
Escherichia coli (%) 4·0% (2·9–5·4) 2·8% (2·0–4·1) 3·7% (3·0–4·5)
Proteus, Providencia, or Morganella 
spp (%)
0·3% (0·1–0·9) 0·4% (0·2–1·0) 0·2% (0·1–0·5)
Klebsiella, Enterobacter, Serratia, or 
Citrobacter spp (%)
3·4% (2·4–4·7) 4·8% (3·7–6·3) 2·7% (2·1–3·4)
At ICUs using rapid screening n=983 n=906 n=2351
Any (%) 12·3% (10·4–14·5) 11·0% (9·2–13·2) 14·1% (12·7–15·5)
MRSA (%) 3·3% (2·3–4·6) 4·6% (3·5–6·2) 3·3% (2·6–4·1)
VRE (%) 3·5% (2·5–4·8) 2·2% (1·4–3·4) 5·8% (4·9–6·8)
HRE
Total (%) 7·0% (5·6–8·8) 5·7% (4·4–7·5) 7·7% (6·7–8·8)
Escherichia coli (%) 2·7% (1·9–4·0) 2·2% (1·4–3·4) 3·8% (3·1–4·6)
Proteus, Providencia, or Morganella spp (%) 0·3% (0·1–0·9) 0·0% (0·0–0·4) 0·2% (0·1–0·5)
Klebsiella, Enterobacter, Serratia, or 
Citrobacter spp (%)
4·8% (3·6–6·3) 3·6% (2·6–5·1) 4·2% (3·5–5·1)
Data are mean (95% CI). Excludes patients for whom both the admission swab was not obtained during the ﬁ rst 2 days 
after admission, and the ﬁ rst swab taken during ICU admission was positive. MRSA=meticillin-resistant Staphylococcus 
aureus. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. ICU=intensive care unit.
Table 2: Carriage of antimicrobial-resistant bacteria at admission to ICU
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which was less than 10% except during phase 3 in the 
rapid screening group (13%). Therefore, the scarcity of 
single rooms was unlikely to have decreased the quality of 
isolation procedures during phase 3. In phase 3, median 
turn-around time was 48 h for chromogenic tests, and 24 h 
for PCR (appendix, table 3). 
We analysed 64 997 swabs in total. At admission to ICU, 
296 (3·6%) of 8184 patients were colonised with MRSA, 
384 (4·7%) of 8243 were colonised with VRE, and 1014 
(12·8%) of 7943 were colonised with HRE. Molecular 
analysis of ﬁ rst isolates at the central laboratory 
conﬁ rmed identiﬁ cation for 508 of 553 (92%) isolates for 
MRSA. For VRE, 346 of 672 (51%) isolates were vanA or 
vanB containing Enterococcus faecium and Enterococcus 
faecalis, and 235 (35%) were Enterococcus gallinarum and 
Enterococcus casseliﬂ avus. Of 2129 HRE isolates, 1966 
(92%) produced extended-spectrum β lactamases, of 
which 571 (29%) were also resistant to carbapenems, and 
241 (12%) produced AmpC.
The baseline acquisition rate of antimicrobial-resistant 
bacteria and trends varied widely between centres 
(appendix), with a baseline trend (weekly incidence rate 
ratio) of 1·014 (95% CI 0·996–1·031; table 3). Trend in 
acquisition of antimicrobial-resistant bacteria decreased 
during phase 2 with no evidence of a stepwise change in 
incidence between phases 1 and 2. For phase 3, there was 
no incremental eﬀ ect on acquisition of antimicrobial-
resistant bacteria (table 3, ﬁ gure 3). When comparing the 
rapid and conventional screening groups, we found no 
evidence of diﬀ erences in trends of acquisition of 
antimicrobial-resistant bacteria, though there was evidence 
of a stepwise diﬀ erence in the rapid screening group 
associated with a higher acquisition rate (table 3). However, 
using a combined test of both possible eﬀ ects (step 
changes and changes to trend), we found no strong 
evidence to reject the null hypothesis of no overall 
diﬀ erence between rapid and conventional groups 
(p=0·06; likelihood ratio test).
Trends in acquisition of MRSA rose during phase 1 and 
fell during phase 2, resulting in a mean weekly decrease of 
3·6%, with no substantial step change in phase 2. No 
substantial step change occurred during phase 3, while 
trends in MRSA acquisition increased (table 3). Step 
changes and changes in trends of MRSA acquisition were 
similar in the conventional screening and rapid screening 
groups (table 3, appendix). For HRE and VRE, we found 
no evidence of step changes in acquisition or trends in 
either phase 2 or phase 3; acquisition in  each screening 
group was also much the same (table 3, appendix). Cox 
regression conﬁ rmed the results of the Poisson model and 
suggested that trends in acquisition during each phase 
could not be wholly explained by changes in colonisation 
pressure. This analysis also provided some evidence that 
the phase 2 intervention led to a trend for reduced 
acquisition of VRE (appendix). Much the same results 
were obtained for only MRSA and VRE grouped together 
in an unplanned post-hoc analysis (data not shown).
The total number of ICU-acquired ﬁ rst bacteraemias 
recorded during the trial was 72 HRE, 28 MRSA, and 
nine VRE (E faecium and E faecalis only). Overall ICU-
acquired bacteraemia caused by antimicrobial-resistant 
bacteria did not diﬀ er signiﬁ cantly between phases or 
between intervention groups in phase 3 (appendix). The 
trend in ICU-acquisition of HRE bacteraemia fell in 
phase 1, but not in phase 2, phase 3, or in the screening 
groups. For MRSA and VRE, numbers were too low to do 
statistical analyses.
Mean length of stay in ICU for patients at risk for 
acquisition of antimicrobial-resistant bacteria was 
8 days in phase 1. Trend in phase 2 was 0·988 (95% CI 
0·982–0·994); a net reduction of 26% (16–48) at the end 
of phase 2. For phase 3, trend for length of stay in ICU 
was 1·180 (95% CI 1·006–1·384) for ICUs using rapid 
screening compared with 1·082 (0·921–1·270) for those 
using conventional screening. Rapid screening, but not 
conventional screening, was also associated with a 
stepwise increase for phase 3. There was no evidence 
that hospital length of stay and mortality at day 28 were 
aﬀ ected by any of the interventions (appendix). We 
assessed 223 MRSA isolates for qacA or qacB: we 
detected the genes in 14 of 110 isolates from phase 1 
and in 16 of 113 isolates from phase 3 (p=0·75; data 
not shown).
Discussion
Improved hand hygiene combined with universal 
chlorhexidine body-washing was associated with reduced 
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Figure 2: Mean hand hygiene compliance per month
Hand hygiene improvement intervention introduced at month 0. Error bars are 95% CIs.
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acquisition of antimicrobial-resistant bacteria, mainly by 
reduction of MRSA acquisition. The same interventions 
did not reduce acquisition of HRE or VRE. 
Implementation of contact precautions for carriers 
identiﬁ ed by either chromogenic or PCR screening had 
no incremental eﬀ ect on acquisition. Optimum hand 
hygiene and universal chlorhexidine body-washing was 
also associated with reduced length of stay in ICU, and 
Antimicrobial-resistant bacteria MRSA VRE HRE
Phase 1 trend 1·014 (0·996–1·031; p=0·12) 1·042 (1·010–1·075; p=0·01) 1·000 (0·971–1·030; p=0·99) 1·012 (0·992–1·032; p=0·25)
Phase 2 step change 0·955 (0·676–1·348; p=0·79) 1·159 (0·654–2·053; p=0·61) 0·884 (0·481–1·626; p=0·69) 0·831 (0·559–1·235; p=0·36)
Phase 2 change in trend 0·976 (0·954–0·999; p=0·04) 0·925 (0·890–0·962; p<0·001) 0·982 (0·945–1·020; p=0·36) 0·994 (0·968–1·021; p=0·66)
Phase 3 step change 0·634 (0·349–1·153; p=0·14) 0·755 (0·252–2·257; p=0·62) 0·651 (0·209–2·031; p=0·46) 0·525 (0·263–1·048; p=0·07)
Phase 3 change in trend 1·015 (0·998–1·032; p=0·09) 1·057 (1·029–1·086; p<0·001) 1·015 (0·984–1·048; p=0·34) 0·991 (0·971–1·011; p=0·35)
Phase 3 step change (rapid vs conventional 
screening)
1·696 (1·090–2·638; p=0·02) 1·734 (0·768–3·916; p=0·19) 1·735 (0·711–4·234; p=0·23) 1·691 (1·012–2·828; p=0·05)
Phase 3 change in trend (rapid vs conventional 
screening)
0·996 (0·984–1·007; p=0·46) 0·985 (0·966–1·005; p=0·15) 0·993 (0·969–1·018; p=0·59) 1·000 (0·986–1·014; p=0·99)
Likelihood ratio test (rapid vs conventional 
screening)
p=0·06 p=0·34 p=0·47 p=0·10
Data are IRR (95% CI) unless stated otherwise. IRR <1 represents a decrease in acquisition, whereas IRR >1 represents an increase. Cluster eﬀ ects were accounted for in the analyses, and potential confounding 
factors (sex, age, month, invasive devices, nurse-to-patient staﬃ  ng ratio, location before ICU admission, reason for admission, APACHE/SAPS, hospital, and number of days-at-risk for acquisition) were ﬁ tted as 
covariates. MRSA=meticillin-resistant Staphylococcus aureus. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. IRR=incidence rate ratio. APACHE=Acute Physiology and Chronic 
Health Evaluation. SAPS=Simpliﬁ ed Acute Physiology Score. 
Table 3: Weekly acquisition of any antimicrobial-resistant bacteria, MRSA, VRE, and HRE
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Figure 3: Acquisition of antimicrobial-resistant bacteria and meticillin-resistant Staphylococcus aureus per 100 patient-days at risk
For all antimicrobial bacteria in both screening groups (A), for MRSA in both screening groups (B), for all antimicrobial bacteria in the conventional screening group 
(C), for MRSA in the conventional screening group (D), for all antimicrobial bacteria in the rapid screening group (E), and for MRSA in the rapid screening group (F). 
Shaded area is the start of phase 3. Green dots are data; green lines are 7 week moving average. Red lines are expected values from the multilevel Poisson segmented 
regression model. Cluster eﬀ ects were accounted for, and potential confounding factors (sex, age, month, invasive devices, nurse-to-patient staﬃ  ng ratio, location 
before ICU admission, reason for admission, APACHE and SAPS score, hospital, and number of days-at-risk for acquisition) were ﬁ tted as covariates. APACHE=Acute 
Physiology and Chronic Health Evaluation. SAPS=Simpliﬁ ed Acute Physiology Score. 
Articles
www.thelancet.com/infection   Vol 14   January 2014 37
addition of PCR-based screening was associated with 
increased length of stay in ICU.
Three cluster randomised studies of ICUs in the USA 
have evaluated similar interventions. Huskins and 
colleagues25 showed no change in acquisition of MRSA 
and VRE after universal screening of patients and pre-
emptive isolation followed by barrier precautions for 
identiﬁ ed carriers. However, average turn-around time of 
admission screening was 5·2 days, implying that many 
screening results were not available before patient 
discharge.18,19,25
In a cluster-crossover study of nine ICUs, Climo and 
coworkers8 compared daily bathing with chlorhexidine-
impregnated washcloths to non-antimicrobial wash-
cloths. The intervention reduced acquisition of VRE, but 
not MRSA, and was associated with a signiﬁ cant 
reduction in primary bloodstream infections, primarily 
caused by a reduced incidence of coagulase-negative 
staphylococci bacteraemia. Moreover, the analysis did 
not account for clustering eﬀ ects and might therefore 
have overestimated the statistical signiﬁ cance of the 
ﬁ ndings. In the third study,9 74 ICUs were randomly 
assigned to one of three groups: MRSA screening and 
isolation; targeted decolonisation; and universal 
decolonisation with mupirocin nasal ointment com-
bined with chlorhexidine body-washing. Universal 
decolonisation was associated with signiﬁ cant reductions 
of clinical cultures yielding MRSA, and all-cause 
bloodstream infections, but not MRSA bloodstream 
infections.
None of these studies addressed the beneﬁ cial eﬀ ects of 
hand hygiene improvement. In our study, the gradual 
decrease in acquisition of antimicrobial-resistant bacteria 
in phase 2 coincided with a gradual increase in hand 
hygiene compliance, suggesting that hand hygiene 
improvement might have been an important component 
of the intervention since chlorhexidine body-washing was 
successfully implemented immediately in phase 2 
(appendix). However, our study design precludes 
assessment of the relative importance of these two 
interventions.
Our ﬁ ndings add to the growing body of evidence that, 
in high endemicity settings, screening for MRSA carriage 
followed by implementation of barrier precautions is of 
little eﬀ ectiveness for prevention of transmission.9,25–28 The 
failure to reduce HRE acquisitions might be explained—
at least in part—by diﬀ erences in bacterial epidemiology. 
Whereas HRE mainly colonise the digestive tract, MRSA 
and VRE can also colonise the skin and environment. 
Thus, patient-to-patient transmission might not be the 
main route of acquisition for HRE in ICUs, and other 
prevention methods will be needed to reduce colonisation 
and infections with HRE, such as antibiotic stewardship 
programmes or intestinal decolonisation with non-
absorbable antibiotics (panel).13,14,29–31
Our study has some limitations. With 13 ICUs in eight 
countries, many diﬀ erences in resistance and unit 
characteristics existed. However, in unplanned 
explanatory subgroup analyses, intervention eﬀ ects did 
not diﬀ er signiﬁ cantly between wards with high and low 
median prevalence of MRSA, VRE, or HRE at admission. 
Panel: Research in context
Systematic review
We searched PubMed with the terms (“clinical trials as topic”[MeSH Terms]) AND 
((“anti-infective agents”[Pharmacological Action] OR “anti-infective agents”[MeSH Terms] 
OR (“anti-infective”[All Fields] AND “agents”[All Fields]) OR “anti-infective agents”[All 
Fields] OR “antimicrobial” AND resistance) AND (“intensive care”[MeSH Terms]) AND 
(“infection control”[MeSH Terms])) which returned 66 articles, of which we excluded those 
testing drug prophylaxis (eg, selective digestive decontamination or surgical prophylaxis) or 
testing prevention of speciﬁ c infections (eg, catheter-related or respiratory infections) or 
non-resistant microorganisms and studies done outside intensive care units (ICUs). Related 
citations and authors’ personal references lists were also searched. We identiﬁ ed eight 
articles, including four systematic reviews. One was a systematic review32 of screening for 
meticillin-resistant Staphylococcus aureus (MRSA), which included 48 studies, of which 
14 were done in ICUs, but did not include the most recent and largest study by Huang and 
colleagues.9 This meta-analysis concluded that the available evidence was insuﬃ  cient to 
assess the eﬀ ect of screening of ICU patients for MRSA carriage on MRSA acquisition, and 
evidence was insuﬃ  cient to support or refute that, compared with no screening, screening 
for MRSA carriage in ICU patients decreases healthcare-associated MRSA infection or 
bloodstream infection. An individual-patient randomised controlled trial not included in this 
review found no eﬀ ect of screening and isolation on MRSA acquisition rates.33 Further 
evidence against routine screening has been provided by the study by Huang and 
colleagues,9 showing no signiﬁ cant reduction in MRSA acquisition or bloodstream infection 
with screening and isolation, but reduced rates with decolonisation strategies using 
chlorhexidine and mupirocin. Three systematic reviews24,34,35 of chlorhexidine bathing were 
done before publication of the study by Climo and coworkers,8 the results of which favoured 
the intervention when studying rates of acquisition of MRSA and vancomycin-resistant 
enterococci, without evidence of eﬃ  cacy against multidrug-resistant Gram-negative 
bacteria. There was only one randomised controlled trial of isolation and segregation of 
colonised patients, which showed no eﬃ  cacy of this measure on MRSA acquisition rate.36 No 
controlled study addressed the eﬀ ectiveness of hand hygiene or the preventive eﬃ  cacy of 
the above measures on rates of acquisition of multidrug-resistant Gram-negative bacteria in 
ICU patients.
Interpretation
Our study addresses the eﬀ ect of hand hygiene in combination with chlorhexidine bathing 
and of screening and isolation on the prevention of acquisition of major 
antimicrobial-resistant pathogens (multidrug-resistant bacteria, including MRSA, 
vancomycin-resistant enterococci, and highly resistant Enterobacteriaceae) in ICUs. 
Improved hand hygiene and chlorhexidine bathing are associated with a reduction in 
acquisition, mainly through reduced acquisition of MRSA, whereas no eﬀ ect on highly 
resistant Enterobacteriaceae was evidenced. Screening and isolation of carriers did not 
further reduce acquisition of multidrug-resistant bacteria, whether screening was done with 
rapid testing or conventional testing. Our results show the eﬃ  cacy of improved hand 
hygiene to reduce MRSA acquisition rates, and concur with other studies7,8 of the eﬃ  cacy of 
chlorhexidine body-washing. Our ﬁ nding of a lack of added preventive eﬃ  cacy of screening 
and isolation of carriers is also consistent with several large recent controlled studies9,25 
showing little or no eﬃ  cacy of such an approach to reduce acquisition of MRSA or VRE in 
ICUs; however, this ﬁ nding might not apply to settings with lower hand hygiene compliance. 
Lastly, the absence of an eﬀ ect of any of our interventions on highly resistant 
Enterobacteriaceae suggests that new methods to control this emerging threat—eg, 
selective digestive decontamination—should be investigated.
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Furthermore, the eﬀ ectiveness of interventions did not 
vary with diﬀ erences according to baseline trends or 
levels (data not shown). The 95% CIs for primary and 
secondary outcomes were generally small. Because the 
participating ICUs represent typical ICU populations, we 
believe that their heterogeneity and the consistent results 
for high and low prevalence wards add to the external 
validity of our results.
Absence of screening at admission for all patients could 
have biased the results if missing screens did not occur at 
random. However, only new colonisation on day 3 or later 
was deemed acquired in the ICU. Of the patients admitted 
for at least 3 days (and thus at risk for acquisition), 95% 
had admission and discharge data available and at least 
one nasal, rectal, or wound swab during ICU stay. Of the 
patients admitted for at least 5 days, 96% had at least one 
screening swab after admission. Any such bias, if present, 
is therefore likely to be small.
We did not expect the large changes in length of stay, 
which could have aﬀ ected the number of acquisitions of 
antimicrobial-resistant bacteria (and therefore the 
Poisson regression results). However, the very similar 
results obtained by Cox regression analysis (which takes 
the acquisition rate into account) suggest that changes in 
rates cannot be explained by changes in length of stay. 
Knowledge of antimicrobial-resistant bacteria carriage in 
phase 3 might have caused some delay in discharge of 
patients. The increasing length of stay during phase 3 
aﬀ ected both groups but was larger in the rapid screening 
group. This diﬀ erence might be because more patients 
were identiﬁ ed as carriers in this group and such patients 
were identiﬁ ed earlier. We cannot comment on the risk 
of transmission of antimicrobial-resistant bacteria after 
ICU discharge, because it was not measured.
All participating laboratories used standardised pro-
cedures to process samples, and completed quality 
assess ments for detection of MRSA, VRE, and HRE.20–22 
Con ﬁ rmation rates at the central laboratory were high 
for MRSA and HRE. For VRE only 51% of isolates 
contained vanA or vanB. However, analyses using only 
conﬁ rmed vanA or vanB data did not change our results 
(data not shown).
A further limitation is that improved hand hygiene 
combined with universal chlorhexidine body-washing 
was not protected by randomisation and is potentially 
vulnerable to maturation eﬀ ects. However, the primary 
analysis adjusted for seasonal eﬀ ects, and accounted for 
ICU-speciﬁ c levels and trends in the baseline period. 
Moreover, visual inspection of MRSA outcomes in the 
two study groups shows a similar decrease during 
phase 2. Finally, patient isolations were assessed from 
weekly point-prevalence, and not monitored on a daily 
patient-level basis and adherence to contact precautions 
was not audited.
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